Our research at Maccabitech covers many therapeutic areas and our epidemiologists have expertise in a wide range of medical fields. Their highly thorough and fast-paced research has led to many groundbreaking medical accomplishments, earning Maccabitech its reputation for excellence.
Featured Research Projects
Neurologic disorders have devastating effects on patients and families as well as a high societal cost burden. There are limited sources of high-quality, longitudinal, multimodal real world data to advance clinical research in this area.
eNLIGHTEN is a partnership between Roche PD-PHC and Maccabi Healthcare Services (MHS) which aims to address the current challenges, advance research, and improve health outcomes in neurodegenerative disorders (Alzheimer’s disease, Huntington disease & Parkinson’s disease).
Primary Maccabitech Researcher: Yael Barer
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
In January 2020, the multinational observational CVD-REAL 3 study, was published in
The LANCET. In this real-world study of patients with type 2 diabetes mellitus (T2DM), initiation of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor therapy was associated with a slower rate of kidney function decline and lower risk of major kidney events compared with initiation of other glucose-lowering drugs.
This study was sited in "KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease" (CKD), which recommends that patients with T2DM and CKD with an eGFR higher than 30 ml/min per 1.73 m2, should considered to be treated with SGLT2 inhibitors together with metformin.
Epidemiology of Hepatitis C Virus infection in a large Israeli health maintenance organization
The treatment landscape for hepatitis C virus (HCV) infection evolved rapidly in recent years with the introduction of direct-acting antivirals (DAA). Using the Maccabi Healthcare Services database, more than 10 thousand patients were identified with HCV infection at the end of 2012 (age-adjusted prevalence of 0.5%).
Results indicated that while the reported incidence of HCV infection in Israel is declining, prevalence is particularly high among immigrants from the former Soviet Union and genotype 1 is predominant. These data contributed to informing health technology assessments for new DAAs.
Early diagnosis of Gaucher disease: using real-world data for development of an advanced machine learning algorithm (in progress)
Gaucher’s disease (GD) is a rare genetic disorder. Its early diagnose poses a significant challenge to non-GD specialties due to the wide variability in age, severity, type of clinical manifestation and lack of awareness of GD early signs and symptoms.
The main study goal is to develop a predictive model for accurately diagnosing GD based on real-world clinical data. The development of an algorithm for diagnosing patients with rare diseases like GD, using a large database and machine learning, may lead to changing the rare diseases diagnostic approach in the future.
Osteoporosis in the community: findings from a novel computerized registry in a large health organization
Osteoporosis is a growing public health concern due to its rising prevalence and excess morbidity and mortality. This research project constructed an automated patient registry for osteoporosis, which is a great importance in health and disease management. These types of registries are rarely used for osteoporosis.
Patients included in the registry were adults who were diagnosed with osteoporosis, had major osteoporotic fractures, or purchased relevant medications. In addition, patients with low bone density as extracted from over 140,000 measurements reports, using an automated optical character recognition (OCR) system, were also included. Two-thirds of the cases were validated by more than one inclusion criterion.
This is one of the first real-world automated registries of osteoporosis. Similar registries may provide valuable data for real-time monitoring of trends, quality of care, and outcome research in osteoporosis and its complications.